Search results for "EPATOCARCINOMA"
showing 10 items of 33 documents
Valutazione della risposta al trattamento con termoablazione percutanea con radiofrequenza dell’epatocarcinoma: ruolo dell’ecografia con mezzo di con…
2006
Risposta al trattamento mediante ablazione percutanea con radiofrequenza dell’epatocarcinoma: valutazione tramite ecografia con mezzo di contrasto (C…
2008
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy
2011
A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or inter…
PATOGENESI MOLECOLARE DELL'EPATOCARCINOMA E TERAPIA FARMACOLOGICA.
2012
Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells
2015
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of sorafenib was evaluated. The obtained systems showed characteristics suitable as drug delivery systems for the treatment of hepatocellular carcinoma (HCC) through parenteral administration. The use of a mixture between a solid lipid (tripalmitin) with a liquid lipid (Captex 355 EP/NF or Miglyol 812) to prepare NLC systems could give a higher drug loading capacity and a longer term stability during storage than that obtained by using only solid lipids. The obtained nanoparticles showed a nanometer size and high negative zeta potential values. Scansion electron microscopy (SEM) of the sorafenib loaded NLC…
Fattori di rischio influenzanti la sopravvivenza dei pazienti con epatocarcinoma su cirrosi sottoposti a diversi tipi di trattamento
2011
MIRNA NEL CARCINOMA EPATOCELLULARE
Cationic solid lipid nanoparticles complexed with genetic material for liver tumor treatment
2015
Concept Gene therapy is a growing field of medicine with great potential for the treatment of several diseases and it is based on the delivery of nucleic acids (DNA, RNA, etc.,) to specific cells. To achieve their therapeutic effects, the nucleic acids need to cross several biological barriers and be protected from the degradation by nucleases, present in biological fluids and intracellular compartments, to successfully gain access to their intracellular targets. To overcome these hurdles, it is necessary to deliver the genetic material with biocompatible carriers able to facilitate its translocation across the cell membranes and protect it from being degraded while circulating in the blood…
IL PARTENOLIDE SENSIBILIZZA CELLULE DI EPATOCARCINOMA UMANO ALL' APOPTOSI INDOTTA DA TRAIL
2011
Papel de IRS2 en la reparación del daño hepático y cáncer
2019
La resistencia a insulina es una característica típica de la diabetes tipo 2 y la obesidad, patologías vinculadas a un alto riesgo del desarrollo de enfermedades crónicas hepáticas y hepatocarcinoma. Sin embargo, se desconoce el papel que la resistencia a insulina pueda ejercer durante el daño hepático crónico y durante la hepatocarcinogénesis, por lo que se ha abordado esta cuestión a través del estudio del substrato receptor de insulina 2 (IRS2), principal promotor de la señalización de insulina en el hígado. La experimentación llevada a cabo durante este proyecto muestra que la deleción del gen Irs2 en el modelo murino Irs2-/- impide la inducción de Fgf7 en células estromales durante el …